AGM
GNMK

Alpine Global Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Alpine Global Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27,615
Closed -$133K – 523
2019
Q4 		$133K Buy
+27,615
New +$152K 0.03% 349

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpine Global Management's GNMK Position: Q1 2020 in Review

Alpine Global Management sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2020, closing a stake of 27,615 shares — an estimated $133K sold.

Alpine Global Management first reported a position in GNMK in Q4 2019 and held it in 1 quarter. The position peaked at $133K in Q4 2019. 110 funds tracked by Wall St. Rank hold GNMK as of Q1 2020.

  • Alpine Global Management reported no remaining GenMark Diagnostics, Inc position as of Q1 2020 after selling out during the quarter.
  • Alpine Global Management sold 27,615 GenMark Diagnostics, Inc shares in Q1 2020, an estimated $133K.
  • Alpine Global Management first reported a position in GenMark Diagnostics, Inc in Q4 2019 and held it in 1 quarter.
  • Alpine Global Management's GenMark Diagnostics, Inc position peaked at $133K in Q4 2019.
  • 110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.